Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.88 USD
Change Today -0.22 / -7.10%
Volume 1.7M
BIOC On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

biocept inc (BIOC) Snapshot

Open
$3.08
Previous Close
$3.10
Day High
$3.14
Day Low
$2.72
52 Week High
06/20/14 - $7.72
52 Week Low
02/10/15 - $1.09
Market Cap
46.0M
Average Volume 10 Days
4.7M
EPS TTM
$-4.37
Shares Outstanding
16.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCEPT INC (BIOC)

Related News

No related news articles were found.

biocept inc (BIOC) Related Businessweek News

No Related Businessweek News Found

biocept inc (BIOC) Details

Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options; OncoCEE-LU, a test for non-small cell lung cancer; and OncoCEE-GA for gastric cancer. The company is also developing other OncoCEE CTC tests, including OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma, as well as CEE-Selector, a sequencing application for various cancer types. It sells its cancer diagnostic tests directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. The company was founded in 1997 and is headquartered in San Diego, California.

42 Employees
Last Reported Date: 03/11/15
Founded in 1997

biocept inc (BIOC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $418.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $255.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $208.2K
Vice President of Commercial Operations
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2014.

biocept inc (BIOC) Key Developments

Biocept, Inc. Enters Clinical Collaboration with University of California, San Diego Moores Cancer Center

Biocept, Inc. and announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the clinical utility of detecting biomarkers present in CTCs and ctDNA in blood samples for non-small cell lung cancer patients using Biocept's OncoCEE LU platform and CEE-Selector technology. Biocept offers a highly sensitive and quantitative blood-based method for the detection and monitoring of cancer mutations, which can help inform treatment decisions based on genomic information. The company is engaged in clinical study collaborations designed to demonstrate the utility of its liquid biopsy diagnostics to detect biomarker status in cancer patients, and for the assessment of tumor treatment response over time.

Biocept, Inc. Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for Egfr Mutations

Biocept, Inc. announced the launch of its EGFR mutation detection testing utilizing a patient's blood-based liquid biopsy. This innovative diagnostic has the potential to help physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments. The identification of these mutations in patients with advanced NSCLC can provide them with the opportunity to receive optimal targeted therapies, known as Tyrosine Kinase Inhibitors (TKIs). In the United States, there are two FDA-approved TKI therapies for patients with specific EGFR mutations: Erlotinib, marketed as Tarceva by Genentech, Inc.; and Afatinib, marketed as Gilotrif by Boehringher Ingelheim GmbH.

Biocept, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Biocept, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, revenues were $76,000 compared with $19,000 for the same period in 2013, an increase of 300%. The increase was primarily related to higher commercial test volume, partially offset by lower Dana Farber Cancer Institute sample volume as the trial's enrollment approached completion. Net loss was $3,881,541, or $0.87 per basic and diluted share based on weighted average shares outstanding of approximately 4,450,000. This is compared to a net loss of approximately $2,472,009 or $13.57 per basic and diluted share for the fourth quarter of 2013. The increase in net loss was primarily due to the deployment of the company's sales and marketing function, additional expenses associated with becoming a publicly traded company in February 2014, as well as increased research and development costs to bring new tests and biomarkers to market. Loss from operations was $3,731,259 against $2,058,546 a year ago. Loss before income taxes was $3,880,835 against $2,472,009 a year ago. For the year, revenues were $133,415 compared with $134,245 for the same period in 2013. Net loss was $15,866,046, or $3.97 per basic and diluted share based on weighted average shares outstanding of approximately 4,450,000. This is compared to a net loss of $9,233,183 or $50.80 per basic and diluted share for the same period in 2013. Loss from operations was $13,873,924 against $7,944,431 a year ago. Loss before income taxes was $15,864,540 against $9,232,383 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $2.88 USD -0.22

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.62 USD 0.00
BioMerieux €98.06 EUR +0.84
Fluidigm Corp $42.47 USD -0.73
Illumina Inc $189.59 USD -3.01
Laboratory Corp of America Holdings $126.93 USD +0.55
View Industry Companies
 

Industry Analysis

BIOC

Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 96.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 267.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.